Zortemib

Zortemib™ 2mg is a specialized prescription oncology medication containing Bortezomib (2 mg) as a sterile, lyophilized powder intended to be diluted for intravenous infusion. It belongs to a targeted class of medicines known as proteasome inhibitors. By blocking the activity of proteasomes—the enzyme complexes responsible for breaking down regulatory proteins within cells—it disrupts the normal signaling cascade of cancer cells, forcing them into programmed cell death (apoptosis). This therapeutic action is highly effective and primarily indicated for treating patients diagnosed with multiple myeloma and mantle cell lymphoma. Because of its targeted mechanism and severe side-effect profile, administration must be exclusively supervised by a qualified clinical oncologist.